SonoThera Closes $60.75M Series A Funding

SonoThera, a South San Francisco, CA-based biotechnology company, raised $60.75M in Series A funding.

The round was led by ARCH Venture Partners, with participation from Illumina Ventures, Johnson & Johnson Innovation, JJDC, Vertex Ventures HC, and Medical Excellence Capital Eli Lilly & Company, Alexandria Venture Investments, Lifespan Investments, Formic Ventures, Foothill Ventures, and Wilson Sonsini.

The company intends to use the funds to support the continued development of its ultrasound-guided, nonviral, gene therapy platform and treatments, designed to provide patients with genetic medicines.

Founded by Drs. Kenneth Greenberg, Michael Davidson, and Steve Feinstein, SonoThera is a biotechnology company dedicated to treating the root cause of human disease through genetic therapy. It is developing an ultrasound-guided, nonviral gene therapy platform and treatments designed to provide patients with the next generation of safe and effective genetic medicines. The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body.

FinSMEs

05/12/2022